Literature DB >> 7304580

Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases.

R F Spengler, E A Clarke, C A Woolever, A M Newman, R W Osborn.   

Abstract

Eighty-eight cases with newly diagnosed carcinoma of the endometrium and 177 age-matched neighborhood controls were interviewed to test the hypothesis that exogenous estrogens lead to an increased risk of endometrial cancer. Forth-five per cent of the cases and 22% of the controls reported a history of estrogen use which yielded an odds ratio of 2.9 (confidence interval (Cl) 1.7-5.1). Women with five or more years of estrogen use had an odds ratio of 8.6 (Cl 3.2-23.0). Approximately 80% of the estrogen users had used conjugated equine estrogens. For these women the odds ratio was 4.0 (Cl 1.9-8.4) for daily dosages of more than 1 mg of estrogen. Several sources of bias which might affect the estrogen association were investigated. These included comparability of cases and controls, selection procedures, difference between estrogen users and nonusers, exclusion of controls who had hysterectomy, source of estrogen information, and differential recall. The concept or medical surveillance was evaluated by access to medical care and prior history of dilatation and curettage. The strong association between exogenous estrogen use and endometrial cancer remained after consideration for the effects of these biases.

Entities:  

Keywords:  Age Factors; Americas; Biology; Bleeding; Blood Pressure; Canada; Cancer; Control Groups; Curettage; Developed Countries; Diabetes Mellitus; Diseases; Educational Status; Endocrine System; Endometrial Cancer; Estrogens--side effects; Hormones; Hysterectomy; Income; Information; Information Processing; Interviews; Matched Groups; Menopause; Menstrual Cycle; Neoplasms; North America; Northern America; Parity; Physicians; Physiology; Records; Research Methodology; Residence Characteristics; Signs And Symptoms

Mesh:

Substances:

Year:  1981        PMID: 7304580     DOI: 10.1093/oxfordjournals.aje.a113215

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  9 in total

1.  Noncontraceptive hormone use and risk of breast cancer.

Authors:  C P Yang; J R Daling; P R Band; R P Gallagher; E White; N S Weiss
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 2.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 3.  [The role of progestins].

Authors:  H I Wyss
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 4.  Postmenopausal hormone replacement: are two hormones better than one?

Authors:  H Wood; R Wang-Cheng; A B Nattinger
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

Review 5.  Hormone replacement therapy and the endometrium.

Authors:  K M Feeley; M Wells
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

6.  Comparison of questionnaire information and pharmacy data on drug use.

Authors:  P A Van den Brandt; H Petri; E Dorant; R A Goldbohm; S Van de Crommert
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

7.  Risk factors of female cancers in Ragusa population (Sicily)--1. Endometrium and cervix uteri cancers.

Authors:  R Cusimano; G Dardanoni; L Dardanoni; M La Rosa; G Pavone; R Tumino; L Gafà
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

Review 8.  The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.

Authors:  Kyong Hye Joung; Jae-Wook Jeong; Bon Jeong Ku
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

Review 9.  Estrogen replacement therapy (ERT) in high-risk cancer patients.

Authors:  K A Hutchinson-Williams; J N Gutmann
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.